Emergency immunotherapy: Snake and scorpion antivenoms;Immunothérapie d'urgence: antivenins de serpent et de scorpion

Biologie Aujourd'hui

Volumn 204, Issue 1, 2010, Pages 61-70

  Chippaux, Jean Philippe ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

antivenom; envenomations; Immunotherapy; scorpions; snakes

Indexed keywords

RECOMBINANT VACCINE; VENOM ANTISERUM;

ANIMAL; ARTICLE; BITES AND STINGS; EMERGENCY; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; PASSIVE IMMUNIZATION; SCORPION; SERODIAGNOSIS; SNAKE; SNAKEBITE;

ANIMALS; ANTIVENINS; BITES AND STINGS; EMERGENCIES; HUMANS; IMMUNIZATION, PASSIVE; NEUTRALIZATION TESTS; SCORPIONS; SNAKE BITES; SNAKES; VACCINES, SYNTHETIC;

ANIMALIA; SCORPIONES; SERPENTES;

EID: 78149241203     PISSN: 21050678     EISSN: 21050686     Source Type: Journal    
DOI: 10.1051/jbio/2009042     Document Type: Article

References (48)

1. Abroug F., Elatrous S., Nouira S., Haguiga H., Touzi N., Bouchoucha S., Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet, 1999, 354, 906-909.
2. Audebert F., Urtizberea M., Sabouraud A., Scherrmann J.M., Bon C., Pharmacokinetics of Vipera aspis venom after experimental envenoming in rabbits. J Pharmacol Exp Ther, 1994, 268, 1512-1517.
3. Behring E.A., Kitasato S., Ãœ ber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Deutsch Medizinisch Wochenschrift, 1890, 49, 113-1145.
4. Bokata S., Epidémiologie et prise en charge des morsures de serpent dans la province de Bas-Congo (République Démocratique du Congo). Bull Soc Pathol Exot, 2005, 98, 307-309.
5. Burnouf T., Griffiths E., Padilla A., Seddik S., Stephano M.A., Gutiérrez J.M., Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals, 2004, 32, 115-28.
6. Calmette A., L'immunisation artificielle des animaux contre le venin des serpents, et la thérapeutique expérimentale des morsures venimeuses. CR Soc Biol, 1894, 46, 120-124.
7. Casasola A., Ramos-Cerrillo B., de Roodt A.R., Carbajal Socedo A., Chippaux J.-P., Alagón A., Stock R.P., Paraspecific neutralization of the venom of African species of cobra by an equine antiserum against Naja melanoleuca: a comparative study. Toxicon, 2009, 53, 602-608.
8. Chippaux J.-P., Snake-bites: appraisal of the global situation. Bull WHO, 1998 a, 76, 515-524.
9. Chippaux J.-P., The development and use of immunotherapy in Africa. Toxicon, 1998 b, 36, 1503-1506.
10. Chippaux J.-P., The treatment of snake bites: analysis of requirements and assessment of therapeutic efficacy in tropical Africa. A. Ménez A. (Ed.). Perspectives in molecular toxinology, 2002, John Wiley & Sons, Chichester, pp. 457-72.
11. Chippaux J.-P., Goyffon M., Producers of antivenomous sera. Toxicon, 1983, 21, 739-752.
12. Chippaux J.-P., Goyffon M., Production and use of snake antivenom. In A.T. Tu (Ed.). Reptiles and Amphibian Venoms, 1991, Dekker Inc., New York, 5, pp. 529-555.
13. Chippaux J.-P., Goyffon M., Venoms, antivenoms and immunotherapy, Toxicon, 1998, 36, 823-846.
14. Chippaux J.-P., Goyffon M., Availability of the commercial antivenoms. 13th I.S.T. World Congress on Animal, Plant, Microbial Toxins, Paris (France), 18-22 septembre 2000.
15. Chippaux J.-P., Goyffon M., Epidemiology of scorpionism: a global appraisal. Acta Tropica 2008, 107, 71-79.
16. Chippaux, J.P., Kambewasso A., Morsures de serpent et disponibilité en sérum antivenimeux dans la communauté urbaine de Niamey, Niger. Bull Soc Pathol Exot, 2002, 95, 181-183.
17. 2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans R Soc Trop Med Hyg, 1998, 92, 657-662.
18. 2: results of a clinical trial in Northern Cameroon. Am J Trop Med Hyg, 1999, 61, 1017-1018.
19. Chippaux J.-P., Vieillefosse S., Sall O., Mafouta R., Diallo A., Evaluation de l'incidence des morsures de serpent au Sénégal. Bull Soc Pathol Exot, 2005, 98, 277-282.
20. 2 polyvalent equine antivenom for African snakebites in Benin. Am J Trop Med Hyg 2007, 77, 538-546.
21. Chippaux J.-P., Stock R., Massougbodji A., Review: Methodology of clinical studies dealing with the treatment of envenomation. Toxicon, 2009, soumis.
22. Diffo J.L.D., Dzikouk G., LeBreton M., Ngoa L.E., Chirio L., Moyou R.S., Distribution des sérums antivenimeux au Cameroun. Bull Soc Pathol Exot, 2005, 98, 302-303.
23. Dzikouk G.D., Etoundi Ngoa L.S., Thonnon J., Dongmo A.B., Rakotonirina V.S., Rakotonirina A., Chippaux J.-P. Titrage comparatif de trois sérums antivenimeux d'Afrique sub-saharienne. Bull Soc Pathol Exot, 2002, 95, 144-147.
24. Fayomi B., Massougbodji A., Chobli M., Données épidémiologiques sur les cas de morsures de serpent déclarés au Bénin de 1994 à 2000. Bull Soc Pathol Exot, 2002, 95, 178-180.
25. Felton L.D., Dissociation of the specific protein precipitate of antipneumococcus horse serum, and a comparison with a protein isolated by chemical means from this immune serum. J Immun, 1932, 22, 453-467.
26. Harrison R.A., Hasson S.S., Harmsen M., Laing G.D., Conrath K., Theakston R.D., Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon, 2006, 47, 364-368.
27. Hawgood B.J., Doctor Albert Calmette 1863-1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination. Toxicon, 1999, 37, 1241-1258.
28. Isbister G.K., O'Leary M., Miller M., Brown S.G., Ramasamy S., James R., Schneider J.S., A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. Br J Clin Pharmacol, 2008, 65, 139-143.
29. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G, de Silva H.J., The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 2008, 5, e218
30. Krifi M.N., Savin S., Debray M., Bon C., El Ayeb M., Choumet V., Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy. Toxicon, 2005, 45, 187-198.
31. Nguyen L., Principes de production d'immunoglobulines thérapeutiques hautement purifiées. Biologie Aujourd'hui, 2010, 204, 55-59.
32. Olvera A., Ramos-Cerrillo B., Estévez J., Clement H., de Roodt A., Paniagua-Solís J., North and South American Loxosceles spiders: development of a polyvalent antivenom with recombinant sphingomyelinases D as antigens. Toxicon, 2006, 48, 64-74.
33. Oukkache N., Rosso J.P., Alami M., Ghalim N., Saïle R., Hassar M., Bougis P.E., Martin-Eauclaire M.-F., New analysis of the toxic compounds from the Androctonus mauretanicus mauretanicus scorpion venom. Toxicon, 2008, 51, 835-852.
34. Phisalix C., Bertrand G., Sur la propriété antitoxique du sang des animaux vaccinés contre le venin de vipère. CR Soc Biol, 1894, 46, 111-113.
35. Porter R.R., Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature, 1958, 182, 670-671.
36. Ramos-Cerrillo B., de Roodt A.R., Chippaux J.-P., Olguín L., Casasola A., Guzmán G., Paniagua-Solís J., Alagón A., Stock R.P., Characterization of a new polyvalent antivenom (Antivipmyn Africa) against African vipers and elapids. Toxicon, 2008, 52, 881-888.
37. Reid H.A., Thean P.C., Martin W.J., Specific antivenene and prednisone in viper-bite poisoning: controlled trial. Br Med J, 1963, 2, 1378-1380.
38. Rivière G., Choumet V., Audebert F., Sabouraud A., Debray M., Scherrmann J.-M., Bon C., Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: Towards an optimization of antivenom therapy. J Pharmacol Exp Ther, 1997, 281, 1-8.
39. Rivière G., Choumet V., Saliou B., Debray M., Bon, C., Absorption and elimination of viper venom after antivenom administration. J Pharmacol Exp Ther, 1998, 285, 490-495.
40. Roux P., Yersin A., Contribution à l'étude de la diphtérie. Ann Inst Pasteur, 1888, 2, 629-49.
41. Sewall H., Experiments on the preventive inoculation of rattlesnake venom. J Physiol, London, 1887, 8, 203-210.
42. Stock R.P, Massougbodji A., Alagón A., Chippaux J.-P., Bringing antivenom to Sub-Saharan Africa. Nature Biotechnol, 2007, 25, 173-177.
43. Theakston R.D., Warrell D.A., Crisis in snake antivenom supply for Africa. Lancet, 2000, 356, 2104.
44. Vázquez H., Chávez-Haro A., García-Ubbelohde W., Mancilla-Nava R., Paniagua-Solís J., Alagón A., Sevcik C., Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers. Toxicon, 2005, 46, 797-805.
45. Visser L.E., Kyei-Faried S., Belcher D.W., Geelhoed D.W., Schagen van Leeuwen J., van Roosmalen J., Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans R Soc Trop Med Hyg, 2008, 102, 445-450.
46. Vitodegni N., Les accidents de la circulation et les traumatismes. La gestion des données. Expérience du Bénin. Conférence africaine sur la sécurité routière, 05-07 février 2007, Accra, Ghana. http://www4.worldbank.org/afr/ssatp/Open.aspx?id=747 accédé le 13 mai 2009.
47. Warrell D.A., Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product-"what"s in a name? Trans R Soc Trop Med Hyg, 2008, 102, 397-399.
48. WHO, Guidelines on Production, Control and Regulation of snake antivenom immunoglobulins, OMS, Genève, sous presse.